TherapeuticsMD erwacht aus seinem Tiefschlaf (Seite 9)
eröffnet am 05.02.21 23:33:31 von
neuester Beitrag 06.06.22 16:55:33 von
neuester Beitrag 06.06.22 16:55:33 von
Beiträge: 113
ID: 1.341.415
ID: 1.341.415
Aufrufe heute: 0
Gesamt: 4.894
Gesamt: 4.894
Aktive User: 0
ISIN: US88338N1072 · WKN: A1W1WN
0,1440
EUR
0,00 %
0,0000 EUR
Letzter Kurs 09.05.22 Berlin
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,4500 | +41,56 | |
| 1,0000 | +33,33 | |
| 0,5500 | +22,22 | |
| 15,348 | +19,53 | |
| 1,6500 | +17,86 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 12,150 | -12,72 | |
| 0,6505 | -13,27 | |
| 5,2500 | -19,23 | |
| 5,0095 | -23,98 | |
| 0,7800 | -29,73 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 66.940.877 von Arctic-Power am 10.02.21 22:29:31Der wohl wichtigste Satz aus dieser Meldung
"All of the shares in the offering are to be sold by TherapeuticsMD."
Keine Shares für die Shorts?
Das ist aber schade
"All of the shares in the offering are to be sold by TherapeuticsMD."
Keine Shares für die Shorts?
Das ist aber schade
TherapeuticsMD Announces Underwritten Public Offering of its Common Stock
February 10, 2021 04:01 PM Eastern Standard Time
BOCA RATON, Fla.--( BUSINESS WIRE )--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the offering. All of the shares in the offering are to be sold by TherapeuticsMD.
Cantor Fitzgerald & Co. is acting as sole bookrunning manager for the offering.
TherapeuticsMD intends to use the net proceeds from the offering for commercialization of its three FDA-approved products, IMVEXXY® (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause, BIJUVA® (estradiol and progesterone) capsules, a hormone therapy combination of bio-identical 17ß-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus, and ANNOVERA® (segesterone acetate/ethinyl estradiol vaginal system), the first and only annual patient-controlled, procedure-free, reversible prescription contraceptive option for women, including to maximize ANNOVERA’s consumer-focused commercialization strategy. TherapeuticsMD additionally may use a portion of the net proceeds from the offering to discharge certain indebtedness currently outstanding under its financing agreement and intends to use a net portion of the proceeds for working capital and general corporate purposes.
TherapeuticsMD has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) with respect to the offering that became effective on May 5, 2020. A preliminary prospectus supplement (including an accompanying prospectus) relating to the offering will be filed with the SEC. Before buying any shares of TherapeuticsMD’s common stock in the offering, you should carefully read the preliminary prospectus supplement and the accompanying prospectus, together with the information incorporated by reference therein. These documents contain important information that you should consider when making your investment decision. TherapeuticsMD’s SEC filings are available to the public from the SEC’s website at www.sec.gov . When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues.
https://flashalert.me/?symbol=TXMD&source=PR&referer=https:/…
February 10, 2021 04:01 PM Eastern Standard Time
BOCA RATON, Fla.--( BUSINESS WIRE )--TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced an underwritten public offering of its common stock. The Company has granted the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of its common stock offered in the offering. All of the shares in the offering are to be sold by TherapeuticsMD.
Cantor Fitzgerald & Co. is acting as sole bookrunning manager for the offering.
TherapeuticsMD intends to use the net proceeds from the offering for commercialization of its three FDA-approved products, IMVEXXY® (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy due to menopause, BIJUVA® (estradiol and progesterone) capsules, a hormone therapy combination of bio-identical 17ß-estradiol and bio-identical progesterone in a single, oral softgel capsule, for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus, and ANNOVERA® (segesterone acetate/ethinyl estradiol vaginal system), the first and only annual patient-controlled, procedure-free, reversible prescription contraceptive option for women, including to maximize ANNOVERA’s consumer-focused commercialization strategy. TherapeuticsMD additionally may use a portion of the net proceeds from the offering to discharge certain indebtedness currently outstanding under its financing agreement and intends to use a net portion of the proceeds for working capital and general corporate purposes.
TherapeuticsMD has filed a shelf registration statement on Form S-3 with the Securities and Exchange Commission (the “SEC”) with respect to the offering that became effective on May 5, 2020. A preliminary prospectus supplement (including an accompanying prospectus) relating to the offering will be filed with the SEC. Before buying any shares of TherapeuticsMD’s common stock in the offering, you should carefully read the preliminary prospectus supplement and the accompanying prospectus, together with the information incorporated by reference therein. These documents contain important information that you should consider when making your investment decision. TherapeuticsMD’s SEC filings are available to the public from the SEC’s website at www.sec.gov . When available, copies of the preliminary prospectus supplement and the accompanying prospectus relating to the offering may also be obtained by contacting Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative, leading healthcare company, focused on developing and commercializing novel products exclusively for women. Our products are designed to address the unique changes and challenges women experience through the various stages of their lives with a therapeutic focus in family planning, reproductive health, and menopause management. The Company is committed to advancing the health of women and championing awareness of their healthcare issues.
https://flashalert.me/?symbol=TXMD&source=PR&referer=https:/…
https://finance.yahoo.com/quote/TXMD/community?p=TXMD
9 hours ago
From the Jan. Presentation:
Anno - Effective Jan 1st, gained first preferred contract with a PBM that covers ~20% of commercial lives Imvexxy - Effective Jan 1st, gained first preferred contract with a PBM that covers ~20% of commercial lives
– Only branded product covered by this PBM - 4 brands now blocked (Premarin® Cream, Intrarosa®, Osphena®, Estring®) When a doctor writes a prescription for one of these brands, it will now not be covered. A patient
must pay full WAC price unless a PA is approved, then the price would be a non-preferred copay
Over 500,000 total VVA prescriptions adjudicated in 2019 by this PBM
They project an increase of prescribing Dr.s in 2021 from 1,200 to 3,700 with the average scripts per Dr. between 9 & 15 (Anno).
They project the Anno scripts through this PBM will be twice those from the regular channels
Breakeven is about $140,000,000
Anno Scripts in 2021 project (right now it looks like 41,300 with no growth) at 57,000 to 76,000 x $1,100 = $62,700,000 to $83,600,000
Imvexxy - 535,000 to 600,000 x $80 = $42,800,000 to $48,000,000
Bijuva -Using the last weekly script number of 2,391 x 52 = 124,332 x $70 = $8.7mm
2021 revenue = $114,200,000 to $140,300,000 plus the vitamins ($6,000,000) = $120mm to $146mm fr a maximum cash burn of around $20mm.
There is a shot at break even by year end...
They had $161mm in cash year end 2020 according to Yahoo. So no dilution with profitability in the foreseeable future...
Seitens TXMD sollen erstmals Ende des Jahres (Q4) Gewinne generiert werden.
Dementsprechend dürfte der Cash Bestand bis dahin reichen.
Bin gespannt auf die aktuellen Zahlen vom 18.02.2021
9 hours ago
From the Jan. Presentation:
Anno - Effective Jan 1st, gained first preferred contract with a PBM that covers ~20% of commercial lives Imvexxy - Effective Jan 1st, gained first preferred contract with a PBM that covers ~20% of commercial lives
– Only branded product covered by this PBM - 4 brands now blocked (Premarin® Cream, Intrarosa®, Osphena®, Estring®) When a doctor writes a prescription for one of these brands, it will now not be covered. A patient
must pay full WAC price unless a PA is approved, then the price would be a non-preferred copay
Over 500,000 total VVA prescriptions adjudicated in 2019 by this PBM
They project an increase of prescribing Dr.s in 2021 from 1,200 to 3,700 with the average scripts per Dr. between 9 & 15 (Anno).
They project the Anno scripts through this PBM will be twice those from the regular channels
Breakeven is about $140,000,000
Anno Scripts in 2021 project (right now it looks like 41,300 with no growth) at 57,000 to 76,000 x $1,100 = $62,700,000 to $83,600,000
Imvexxy - 535,000 to 600,000 x $80 = $42,800,000 to $48,000,000
Bijuva -Using the last weekly script number of 2,391 x 52 = 124,332 x $70 = $8.7mm
2021 revenue = $114,200,000 to $140,300,000 plus the vitamins ($6,000,000) = $120mm to $146mm fr a maximum cash burn of around $20mm.
There is a shot at break even by year end...
They had $161mm in cash year end 2020 according to Yahoo. So no dilution with profitability in the foreseeable future...
Seitens TXMD sollen erstmals Ende des Jahres (Q4) Gewinne generiert werden.
Dementsprechend dürfte der Cash Bestand bis dahin reichen.
Bin gespannt auf die aktuellen Zahlen vom 18.02.2021
Schon über 9 Mio. Shares Umsatz an der Nasdaq
Trading Spotlight
Antwort auf Beitrag Nr.: 66.903.398 von Arctic-Power am 09.02.21 13:44:32Das ist ein eindeutiger short squezze Kandidat..................................
Antwort auf Beitrag Nr.: 66.902.417 von Staind87 am 09.02.21 13:04:49Mein Kursziel klingt ersteinmal irrational.
Fast 100 % des Freefload sind leer verkaufte Aktien.
Das ist auf den ersten Blick keine gute Nachricht.
Auf den 2. Blick rückt TXMD der Gewinnzone immer näher. Das ist wiederum keine gute Nachricht für die Shortseller. Die werden sugsessive eindecken müssen. Diese beliehenen Shares müssen alle irgendwie eingesammelt werden. Im Januar noch 66 Mio. Shares.
Auf der anderen Seite muß es Verkäufer geben, die ihnen die Aktien zurückgeben. Notfalls mit astronomischen Summen.
Ich lehne mich mal entspannt zurück.
Fast 100 % des Freefload sind leer verkaufte Aktien.
Das ist auf den ersten Blick keine gute Nachricht.
Auf den 2. Blick rückt TXMD der Gewinnzone immer näher. Das ist wiederum keine gute Nachricht für die Shortseller. Die werden sugsessive eindecken müssen. Diese beliehenen Shares müssen alle irgendwie eingesammelt werden. Im Januar noch 66 Mio. Shares.
Auf der anderen Seite muß es Verkäufer geben, die ihnen die Aktien zurückgeben. Notfalls mit astronomischen Summen.
Ich lehne mich mal entspannt zurück.
Hey Arctic-Power,
erst einmal vielen Dank für deine Beiträge.
Habe diese schon bei Dare Bioscience gelesen und gute Gewinne mitgenommen.
Nun habe ich noch mal ne Frage, wie kommst du auf ein Kursziel von 20,75 USD?
In welcher Zeit denkst du das dieses Ziel erreicht werden kann? (Tage / Jahre).
Habe nachdem du dieses Thema eröffnet hast direkt ein paar Aktien ins Depot gelegt :-)
erst einmal vielen Dank für deine Beiträge.
Habe diese schon bei Dare Bioscience gelesen und gute Gewinne mitgenommen.
Nun habe ich noch mal ne Frage, wie kommst du auf ein Kursziel von 20,75 USD?
In welcher Zeit denkst du das dieses Ziel erreicht werden kann? (Tage / Jahre).
Habe nachdem du dieses Thema eröffnet hast direkt ein paar Aktien ins Depot gelegt :-)
Antwort auf Beitrag Nr.: 66.899.081 von pati118 am 09.02.21 10:47:14Vorbörslicher Kurs
https://stocktwits.com/symbol/TXMD
https://stocktwits.com/symbol/TXMD
Durchsuchen
